AI Article Synopsis

Article Abstract

The presence of a solitary lung tumor after radical surgery for breast cancer often causes difficulty in the diagnosis and treatment. We report a patient who had previously undergone radical surgery for breast cancer, and who underwent lung surgery. When the patient was 57 years old, she underwent surgical treatment for breast cancer. Six years later, a chest radiograph revealed a solitary mass on the upper lobe of her left lung. A left upper lobectomy was performed, utilizing videoassisted thoracic surgery. The pathological diagnosis, based on hematoxylin and eosin staining, was lung metastasis from breast cancer. The immunohistological findings revealed that the tumor was positive for estrogen receptor, progesterone receptor, and GCDFP-15, and negative for TTF-1 and Napsin A. Although the original breast cancer lesion was positive for the HER2 receptor, the metastatic lung lesion was negative. It has already been reported that the subtypes can change from 1 subtype in the original lesion to another in the metastatic lesion. Adjuvant therapy was administered based on the subtype of the metastatic lesion after the surgery. Therefore, surgical resection is useful for the purpose of reevaluating HER2 receptor status, the results ofwhich can influence the postoperative adjuvant treatment. The patient is now doing well, without any evidence ofrecurrence or metastasis 15 months after surgery.

Download full-text PDF

Source

Publication Analysis

Top Keywords

breast cancer
24
metastasis breast
8
cancer years
8
radical surgery
8
surgery breast
8
her2 receptor
8
metastatic lesion
8
breast
6
cancer
6
surgery
6

Similar Publications

Importance: Endocrine treatments, such as Tamoxifen (TAM) and/or Aromatase inhibitors (AI), are the adjuvant therapy of choice for hormone-receptor positive breast cancer. These agents are associated with menopausal symptoms, adversely affecting drug compliance. Topical estrogen (TE) has been proposed for symptom management, given its' local application and presumed reduced bioavailability, however its oncological safety remains uncertain.

View Article and Find Full Text PDF

Detectability of Al18F-NOTA-HER2-BCH PET for Nodal Metastases in Patients With HER2-Positive Breast Cancer.

Clin Nucl Med

January 2025

From the Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine; Peking University Cancer Hospital and Institute, Beijing, China.

Purpose: The aim of this study was to compare Al18F-NOTA-HER2-BCH and 18F-FDG for detecting nodal metastases in patients with HER2-positive breast cancer on PET/CT.

Patients And Methods: In this retrospective study, 62 participants with HER2-positive breast cancer underwent both Al18F-NOTA-HER2-BCH and 18F-FDG PET/CT. Participants were pathologically confirmed as HER2-positive (IHC 3+ or IHC 2+ with gene amplification on FISH).

View Article and Find Full Text PDF

In the primary analysis of the open-label phase III PRECIOUS study, pertuzumab retreatment combined with trastuzumab plus chemotherapy of physician's choice (PTC) significantly improved investigator-assessed progression-free survival (PFS) compared with trastuzumab plus physician's choice chemotherapy (TC) in patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced/metastatic breast cancer (LA/mBC). Here, we report final overall survival (OS) at the median follow-up of 25.8 months.

View Article and Find Full Text PDF

Purpose: To investigate whether hormone receptor-positive, human epidermal growth factor receptor 2-low (HR+HER2-low) versus HR+HER2-zero early breast cancers have distinct genomic and clinical characteristics.

Methods: This study included HR+, HER2-negative early breast cancers from patients enrolled in the phase III, randomized BIG 1-98 and SOFT clinical trials that had undergone tumor genomic sequencing. Tumors were classified HR+HER2-low if they had a centrally reviewed HER2 immunohistochemistry (IHC) score of 1+ or 2+ with negative in situ hybridization and HR+HER2-zero if they had an HER2 IHC score of 0.

View Article and Find Full Text PDF

Purpose: Financial toxicity (FT) has been linked to higher symptom burden and poorer clinical outcomes for patients with cancer. Despite the availability of validated tools to measure FT, a simple screen remains an unmet need. We evaluated item 12 ("My illness has been a financial hardship to my family and me") of the COmprehensive Score for Financial Toxicity (COST) measure as a single-item FT screening measure.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!